Clinical Trial Update: An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme

View source ↗

Summary

An Italian multicenter retrospective observational study evaluating the clinical characteristics and outcomes of relapsed or refractory diffuse large B-cell lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Bendamustine (Treanda) (bendamustine)
• Polatuzumab Vedotin (Polivy) (polatuzumab vedotin)
• Rituximab (Rituxan) (rituximab)

Snippet

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna | Conditions: DLBCL - Diffuse Large B Cell Lymphoma | Status: ACTIVE_NOT_RECRUITING